Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BASEL, SWITZERLAND AND LONDON AND NEW YORK, SEPT. 08, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED POSITIVE RESULTS FROM ITS PHASE 2 PHOCUS CLINICAL TRIAL EVALUATING MOSLICIGUAT FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD), A PROGRESSIVE AND LIFE-THREATENING CONDITION WITH SIGNIFICANT UNMET MEDICAL NEEDS FOR PATIENTS. THE RESULTS WILL BE PRESENTED TODAY AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) INTERNATIONAL CONGRESS 2026.

ROIVANT ANNOUNCES POSITIVE RESULTS FROM PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) AND UNVEILS ONGOING PHASE 3 PHRONTIER STUDY

WALTHAM, MASS., SEPT. 08, 2026 (GLOBE NEWSWIRE) -- PULMOVANT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO TRANSFORMING THE LIVES OF PATIENTS WITH PULMONARY DISEASES, AND A ROIVANT (NASDAQ: ROIV) COMPANY, TODAY ANNOUNCED POSITIVE RESULTS FROM ITS PHASE 2 PHOCUS CLINICAL TRIAL EVALUATING MOSLICIGUAT FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD), A PROGRESSIVE AND LIFE-THREATENING CONDITION WITH SIGNIFICANT UNMET MEDICAL NEEDS FOR PATIENTS. THE RESULTS WILL BE PRESENTED TODAY AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) INTERNATIONAL CONGRESS 2026.

PULMOVANT ANNOUNCES POSITIVE RESULTS FROM PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) AND UNVEILS ONGOING PHASE 3 PHRONTIER STUDY

WALTHAM, MASS., SEPT. 06, 2026 (GLOBE NEWSWIRE) -- PULMOVANT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO TRANSFORMING THE LIVES OF PATIENTS WITH PULMONARY DISEASES, AND A ROIVANT (NASDAQ: ROIV) COMPANY, TODAY ANNOUNCED THAT RESULTS FROM THE PHASE 2 PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) WILL BE PRESENTED AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) INTERNATIONAL CONGRESS 2026 AT 12:15 CEST (6:15 A.M. ET) ON TUESDAY, SEPTEMBER 8, 2026, BY MARC HUMBERT, MD, PHD, PROFESSOR OF RESPIRATORY MEDICINE AT UNIVERSIT PARIS-SACLAY AND DIRECTOR OF THE FRENCH NATIONAL REFERENCE CENTER FOR PULMONARY HYPERTENSION.

PULMOVANT TO PRESENT TOPLINE RESULTS FROM THE PHASE 2 PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) AT THE ERS CONGRESS 2026 ON TUESDAY, SEPTEMBER 8, 2026

BASEL, SWITZERLAND AND LONDON AND NEW YORK, SEPT. 06, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) AND PULMOVANT TODAY ANNOUNCED THAT RESULTS FROM THE PHASE 2 PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) WILL BE PRESENTED AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) INTERNATIONAL CONGRESS 2026 AT 12:15 CEST (6:15 A.M. ET) ON TUESDAY, SEPTEMBER 8, 2026, BY MARC HUMBERT, MD, PHD, PROFESSOR OF RESPIRATORY MEDICINE AT UNIVERSIT PARIS-SACLAY AND DIRECTOR OF THE FRENCH NATIONAL REFERENCE CENTER FOR PULMONARY HYPERTENSION. ROIVANT WILL ALSO HOST AN INVESTOR CALL AND WEBCAST AT 8:00 A.M. ET ON TUESDAY, SEPTEMBER 8, 2026.

ROIVANT TO PRESENT TOPLINE RESULTS FROM THE PHASE 2 PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) AT THE ERS CONGRESS 2026 ON TUESDAY, SEPTEMBER 8, 2026, AND HOST INVESTOR CALL

BASEL, SWITZERLAND AND LONDON AND NEW YORK, AUG. 27, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED LISRAYA (BREPOCITINIB) 30 MG FOR THE TREATMENT OF ADULTS WITH DERMATOMYOSITIS (DM). LISRAYA IS A PILL TAKEN ONCE DAILY.

ROIVANT ANNOUNCES FDA APPROVAL OF LISRAYA (BREPOCITINIB) FOR ADULTS WITH DERMATOMYOSITIS; NOW AVAILABLE IN THE U.S.

DURHAM, N.C., AUG. 27, 2026 (GLOBE NEWSWIRE) -- PRIOVANT THERAPEUTICS TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED LISRAYA (BREPOCITINIB) 30 MG FOR THE TREATMENT OF ADULTS WITH DERMATOMYOSITIS (DM). LISRAYA IS A PILL TAKEN ONCE DAILY.

PRIOVANT ANNOUNCES FDA APPROVAL OF LISRAYA (BREPOCITINIB) FOR ADULTS WITH DERMATOMYOSITIS; NOW AVAILABLE IN THE U.S.

DURHAM, N.C., AUG. 26, 2026 (GLOBE NEWSWIRE) -- PRIOVANT THERAPEUTICS ANNOUNCED TODAY THE PUBLICATION IN JAMA DERMATOLOGY OF SKIN-SPECIFIC OUTCOMES FROM THE PHASE 3 VALOR TRIAL EVALUATING BREPOCITINIB, A FIRST-IN-CLASS ORAL TYK2 AND JAK1 INHIBITOR, IN ADULTS WITH DERMATOMYOSITIS (DM). PRIMARY EFFICACY AND SAFETY RESULTS FROM THE TRIAL WERE PREVIOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE, INCLUDING BENEFIT ON MEASURES OF SKIN DISEASE, MUSCLE STRENGTH, PHYSICAL FUNCTION, AND STEROID-SPARING.

JAMA DERMATOLOGY PUBLISHES SKIN-SPECIFIC OUTCOMES FROM PHASE 3 VALOR TRIAL OF BREPOCITINIB IN DERMATOMYOSITIS

ALL IMVT-1402 CLINICAL DEVELOPMENT TIMELINES REMAIN ON TRACK, INCLUDING ONGOING STUDIES IN GRAVES' DISEASE (GD), MYASTHENIA GRAVIS (MG), CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP), DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS (D2T RA), SJGREN'S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) CURRENT CASH BALANCE PROVIDES RUNWAY TO THE POTENTIAL LAUNCH OF IMVT-1402 IN GD ROIVANT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON THURSDAY, AUGUST 6, 2026 DURHAM, N.C.

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

CS IS A HIGHLY MORBID, CHRONIC, AND DISFIGURING CONDITION WITH NO APPROVED THERAPIES BREPOCITINIB IS THE FIRST INVESTIGATIONAL THERAPY TO GENERATE A POSITIVE RESULT IN A PLACEBO-CONTROLLED CS STUDY (PHASE 2 BEACON) AND HAS RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION FOR CS GLOBAL PHASE 3 STUDY (BEACON+) IS UNDERWAY, EVALUATING BREPOCITINIB 45 MG ONCE DAILY AGAINST PLACEBO IN 140 PATIENTS ACROSS APPROXIMATELY 70 SITES GLOBALLY; BEACON+ TOPLINE DATA EXPECTED IN CALENDAR YEAR 2028 BREPOCITINIB'S DEVELOPMENT PROGRAM NOW INCLUDES FOUR INDICATIONS WITH ONGOING OR SUCCESSFULLY COMPLETED REGISTRATIONAL TRIALS: DERMATOMYOSITIS (DM), NON-INFECTIOUS UVEITIS (NIU), LICHEN PLANOPILARIS (LPP), AND CS; POTENTIAL NDA APPROVAL AND PRODUCT LAUNCH IN DM EXPECTED BY THE END OF SEPTEMBER 2026 DURHAM, N.C., AUG. 06, 2026 (GLOBE NEWSWIRE) -- PRIOVANT TODAY ANNOUNCED THAT THE FIRST PATIENTS HAVE BEEN ENROLLED IN THE PHASE 3 STUDY EVALUATING BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS).

PRIOVANT ANNOUNCES FIRST PATIENTS ENROLLED IN PHASE 3 STUDY (BEACON+) OF BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)

COMMERCIAL PREPARATIONS FOR BREPOCITINIB IN DERMATOMYOSITIS (DM) ARE PROGRESSING WELL AND ON TRACK FOR LAUNCH BY THE END OF SEPTEMBER 2026; TOPLINE DATA FROM PHASE 3 STUDY IN NON-INFECTIOUS UVEITIS (NIU) EXPECTED IN THE SECOND HALF OF CALENDAR YEAR 2026 FIRST PATIENTS ENROLLED IN THE PHASE 3 STUDY OF BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS), WITH TOPLINE DATA EXPECTED IN CALENDAR YEAR 2028; ENROLLMENT IN PART 1 OF THE PHASE 2B/3 STUDY IN LICHEN PLANOPILARIS (LPP) IS PROGRESSING WELL IMVT-1402 PROOF-OF-CONCEPT TRIAL IN CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) TOPLINE DATA EXPECTED IN THE SECOND HALF OF CALENDAR YEAR 2026; ALL CLINICAL DEVELOPMENT TIMELINES REMAIN ON TRACK FOR IMVT-1402 MOSLICIGUAT PHASE 2 STUDY IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) REMAINS ON TRACK, WITH TOPLINE DATA EXPECTED IN THE SECOND HALF OF CALENDAR YEAR 2026 GENEVANT AND ARBUTUS RECEIVED $950 MILLION FROM MODERNA IN JULY 2026 UNDER $2.25 BILLION SETTLEMENT, WITH ADDITIONAL $1.3 BILLION CONTINGENT ON FAVORABLE RESOLUTION OF MODERNA'S  1498 APPEAL; FILED NEW INTERNATIONAL LAWSUITS AGAINST PFIZER AND BIONTECH COVERING 21 JURISDICTIONS ROIVANT REPORTED CONSOLIDATED CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES OF $3.9 BILLION AS OF JUNE30, 2026, EXCLUDING THE CASH PAYMENT RECEIVED FROM MODERNA IN JULY, SUPPORTING CASH RUNWAY INTO PROFITABILITY ROIVANT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON THURSDAY, AUGUST 6, 2026, TO REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE30, 2026, AND PROVIDE A BUSINESS UPDATE BASEL, SWITZERLAND AND LONDON AND NEW YORK, AUG. 06, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE30, 2026, AND PROVIDED A BUSINESS UPDATE.

ROIVANT REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE30, 2026, AND PROVIDES BUSINESS UPDATE

BASEL, SWITZERLAND AND LONDON AND NEW YORK, JULY 23, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON THURSDAY, AUGUST 6, 2026, TO REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2026, AND PROVIDE A BUSINESS UPDATE.

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2026, AND PROVIDE BUSINESS UPDATE ON THURSDAY, AUGUST 6, 2026

DURHAM, N.C., JULY 23, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC.(NASDAQ:IMVT) TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2026 ON THURSDAY, AUGUST 6, 2026 BEFORE THE MARKET OPENS.

Roivant Sciences Ltd.

ROIV

Price

Financial Reports

No items found.

Press Releases

Roivant Sciences Ltd.

ROIV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ROIV